The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Madison Asset Management Boosts Stake in Charles River Laboratories Amidst Analyst Optimism

A large Intel CPU is centered on an orange background with manufacturing equipment, a worker, and upward financial arrows showing +4.85%.

Madison Asset Management LLC significantly increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, acquiring 12,366 shares. This strategic investment was valued at approximately $1.935 million, signaling confidence in the company's prospects. Concurrently, other institutional investors also made adjustments to their holdings in CRL shares, reflecting broader market interest. Financial analysts maintain a "Moderate Buy" rating for CRL, with an average price target set at $209.46. This target suggests a potential upside from current levels, reinforcing a positive outlook for the biopharmaceutical services provider. The institutional buying activity, coupled with favorable analyst sentiment, underscores a bullish perspective on Charles River Laboratories' future performance.